Celyad Oncology (NASDAQ:CYAD) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Celyad Oncology (NASDAQ:CYAD) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

CYAD has been the topic of several other reports. HC Wainwright cut their price target on shares of Celyad Oncology from $17.00 to $15.00 and set a buy rating on the stock in a report on Friday, August 6th. Jonestrading restated a hold rating on shares of Celyad Oncology in a report on Friday, August 20th.

Celyad Oncology stock opened at $4.40 on Tuesday. Celyad Oncology has a fifty-two week low of $3.76 and a fifty-two week high of $10.31. The stock has a market cap of $68.10 million, a PE ratio of -3.14 and a beta of 1.41. The firm’s 50-day simple moving average is $4.33 and its 200 day simple moving average is $5.58. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.42 and a current ratio of 1.32.

A hedge fund recently bought a new stake in Celyad Oncology stock. OLD Mission Capital LLC acquired a new position in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned 0.07% of Celyad Oncology as of its most recent filing with the Securities & Exchange Commission. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Celyad Oncology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.

See Also: Understanding Options Trading

Get a free copy of the Zacks research report on Celyad Oncology (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.